1. Home
  2. CNXC vs MLYS Comparison

CNXC vs MLYS Comparison

Compare CNXC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$26.46

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.61

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXC
MLYS
Founded
1991
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
CNXC
MLYS
Price
$26.46
$23.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$54.80
$48.67
AVG Volume (30 Days)
1.6M
1.1M
Earning Date
03-24-2026
03-12-2026
Dividend Yield
5.20%
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
$9,825,771,000.00
N/A
Revenue This Year
$5.17
N/A
Revenue Next Year
$2.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.15
N/A
52 Week Low
$24.27
$10.44
52 Week High
$62.14
$47.65

Technical Indicators

Market Signals
Indicator
CNXC
MLYS
Relative Strength Index (RSI) 38.32 36.30
Support Level N/A $12.98
Resistance Level $34.64 $31.09
Average True Range (ATR) 2.15 1.56
MACD -0.47 -0.06
Stochastic Oscillator 23.56 12.94

Price Performance

Historical Comparison
CNXC
MLYS

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: